Calistoga Pharmaceuticals Release: CAL-101, an Oral p110d Isoform-Selective PI3 Kinase Inhibitor, Demonstrates Preclinical Activity in Hematologic Cancer Cells

SEATTLE--(BUSINESS WIRE)--Calistoga Pharmaceuticals, Inc., the leader in the development of isoform-selective PI3 kinase inhibitors for the treatment of cancer and inflammatory diseases, today announced the presentation of data demonstrating that the Company’s oral, p110d(delta) selective PI3 kinase inhibitor CAL-101 has broad preclinical anti-tumor activity against a range of hematologic malignancies. Data were presented in an oral presentation and two poster presentations at the American Society of Hematology’s 50th Annual Meeting and Exposition in San Francisco, CA.